Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer

Peter A Argenta, Inhwa Um, Charlene Kay, David Harrison, Dana Faratian, Thanasak Sueblinvong, Melissa A Geller, Simon P Langdon

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Anti-estrogen therapy appears to have efficacy in a subset of ovarian cancers, as demonstrated in multiple phase II studies. Identifying sensitive patients early in treatment may allow for targeted, low-toxicity primary therapy or prevention of recurrence. We have previously demonstrated that the likelihood of response to letrozole could be improved by patient selection based on estrogen-pathway marker expression. We sought to identify ovarian cancer biomarkers that might indicate sensitivity to fulvestrant, an estrogen receptor antagonist.
Original languageEnglish
Pages (from-to)368-373
Number of pages6
JournalGynecologic Oncology
Issue number2
Publication statusPublished - 30 Jul 2013


Dive into the research topics of 'Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this